NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

The funds will support commercialization of its VeriStrat blood-based test for non-small cell lung cancer, as well as clinical validation studies, product development, and ongoing collaborations with biotechnology and pharmaceutical companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.